Jiuyuan Gene (02566) Surges Over 13% as JY54-2 Injection IND Application Officially Accepted by CDE, Covering Two Indications

Stock News11:10

Jiuyuan Gene (02566) surged over 13%, reaching 13.42% as of press time, at HK$4.31, with a turnover of HK$369,800.

On the news front, Jiuyuan Gene recently announced that the Investigational New Drug (IND) application for its independently developed Class 1 new drug JY54-2 Injection has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. This IND application covers two indications: type 2 diabetes and weight management for obese or overweight populations.

The company plans to conduct a Phase I clinical study of JY54-2 Injection, which aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of JY54-2 Injection in trial participants, providing a basis for subsequent clinical development in the aforementioned two indications.

JY54-2 Injection is a long-acting amylin analog independently developed by the company. This product is a next-generation pH-neutral stable long-acting amylin analog with the potential to be developed into combination formulations with other metabolic drugs such as GLP-1 products. Preclinical trial data show that JY54-2 Injection has demonstrated excellent performance across various indicators in multiple pharmacodynamic and safety studies. Based on its molecular design characteristics and mechanism of action analysis, JY54-2 Injection is expected to support long-acting dosing regimens and demonstrate differentiated clinical application potential in the field of weight management.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment